An Open, Parallel Study Evaluating the Pharmacokinetic Profile, Safety, and Tolerability of a Single Oral Dose of ZX-7101A Tablets in Subjects with Mild or Moderate Liver Insufficiency and Healthy Subjects
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Masiloxavir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Acronyms ZX-7101A-203
- Sponsors Nanjing Zenshine Pharmaceuticals
- 05 Nov 2024 Status changed from recruiting to completed.
- 25 Jan 2023 Status changed from planning to recruiting.
- 04 Feb 2022 New trial record